Q2 Earnings Estimate for ABCL Issued By Leerink Partnrs

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for AbCellera Biologics in a research note issued on Monday, July 7th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings of ($0.16) per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics' Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

Several other brokerages also recently issued reports on ABCL. KeyCorp increased their price objective on shares of AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Truist Financial reduced their target price on shares of AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Finally, Leerink Partners started coverage on AbCellera Biologics in a research note on Monday, July 7th. They issued an "outperform" rating and a $5.00 price target on the stock. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, AbCellera Biologics has a consensus rating of "Buy" and an average price target of $7.50.

AbCellera Biologics Stock Performance

ABCL stock traded down $0.24 during mid-day trading on Wednesday, hitting $4.01. 5,616,222 shares of the company were exchanged, compared to its average volume of 3,494,504. The firm has a market cap of $1.20 billion, a P/E ratio of -7.16 and a beta of 0.62. AbCellera Biologics has a 1-year low of $1.89 and a 1-year high of $4.33. The firm's 50 day simple moving average is $2.82 and its 200 day simple moving average is $2.76.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.02. AbCellera Biologics had a negative return on equity of 15.98% and a negative net margin of 737.56%. The business had revenue of $4.24 million during the quarter, compared to analyst estimates of $7.12 million.

Institutional Investors Weigh In On AbCellera Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABCL. DKM Wealth Management Inc. bought a new position in shares of AbCellera Biologics in the 4th quarter valued at about $29,000. Stratos Wealth Advisors LLC acquired a new position in AbCellera Biologics during the first quarter valued at approximately $27,000. Janney Montgomery Scott LLC bought a new position in AbCellera Biologics in the first quarter valued at approximately $29,000. Balyasny Asset Management L.P. acquired a new position in shares of AbCellera Biologics during the 4th quarter worth approximately $40,000. Finally, Mariner LLC acquired a new position in shares of AbCellera Biologics during the 4th quarter worth approximately $42,000. 61.42% of the stock is owned by institutional investors.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.